BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

International Stem Cell Corporation Announces 41% Increase In Revenues For Third Quarter 2013


11/18/2013 12:20:37 PM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

CARLSBAD, CA--(Marketwired - November 13, 2013) - International Stem Cell Corporation (OTCQB: ISCO) (www.internationalstemcell.com) ("ISCO" or "the Company"), a California-based biotechnology company developing novel stem cell-based therapies and biomedical products, today provided a business update and announced financial results for the three and nine months ended September 30, 2013.

Q3 2013 Highlights:

  • Record revenues of $1.67 million, a 41% increase over the corresponding period of 2012. Lifeline Skin Care sales up 54% and Lifeline Cell Technology sales up 30%. Gross margin stable at 73%.
  • Net cash used in operating cash flows (which exclude capital expenditures and patent costs), reduced to approximately $0.47 million per month compared to $0.57 million per month the corresponding period of 2012.
  • Entered into a clinical research agreement with Duke University for the evaluation of ISCO's stem cell-derived neural stem cells for the treatment of Parkinson's disease. Prof. Mark Stacy, M.D., Vice Dean for Clinical Research, Neurology at Duke University School of Medicine and an internationally recognized leader in the field of Movement Disorders, will be the principal investigator.
  • Convened a key opinion leader meeting bringing together leading experts from throughout North America in the field of cell therapy and movement disorders to obtain feedback and guidance for the IND submission in 2014 for our stem cell-derived neural stem cells for the treatment of Parkinson's disease.
  • Presented the results of the first primate study, carried out in collaboration with the Sanford Burnham Institute of Regenerative Medical, examining the benefits of implanting neural stem cells into primates with chemically-induced parkinsonian symptoms, at the American Neurological Association 2013 Annual Meeting.
  • Obtained gross proceeds of $3.00 million through a public offering, to be used to fund R&D programs.

"We're extremely pleased to report outstanding revenues and growth for the quarter, and having achieved revenues in the three quarters thus far almost equal to those reported for the entire year of 2012. The reduction of cash used in operations is a clear demonstration of the success of our commercial businesses in order to support our core therapeutic activities," stated Dr. Andrey Semechkin, ISCO's CEO and Co-chairman.

"We have significant scientific milestones in the next twelve months and our clinical collaboration with Duke University provides us with the complementary skills and expertise to achieve these goals," Dr. Semechkin concluded.

Three Months Ended September 30, 2013

Revenue for the three months ended September 30, 2013 was $1.67 million, an increase of approximately 41% compared to $1.19 million for the corresponding period in 2012. Sales for Lifeline Skin Care (LSC) and Lifeline Cell Technology (LCT) increased by 54% and 30%, and accounted for 49% and 51% of total revenue, respectively. Cost of sales was $0.45 million, or 27% of revenue, compared to $0.32 million or 27% of revenue in the corresponding period a year ago.

General and administrative expenses for the three months ended September 30, 2013 declined 13% to $1.36 million, driven primarily by lower personnel-related expenses resulting from lower headcount, lower stock-based compensation expenses and lower professional and corporate support expenses.

Marketing expenses increased 32% to $0.63 million compared to the corresponding period of 2012, reflecting higher spending on advertising, trade shows and promotions.

Net cash used in operating cash flows (which exclude capital expenditures and patent costs), reduced to approximately $0.47 million per month compared to $0.57 million per month the corresponding period of 2012.

Nine Months Ended September 30, 2013

Revenue for the nine months ended September 30, 2013 and 2012 was $4.41 million and $3.32 million, respectively. LSC contributed $2.17 million, up 36% from the same period in 2012 and LCT contributed $2.24 million, up 29% from the corresponding period in 2012.

Cost of sales for the nine months ended September 30, 2013 was $1.11 million or 25% of revenue, compared to $0.96 million or 29% of revenue for the corresponding period in 2012 as a result of continued improvements in efficiency and effectiveness in manufacturing and the management of supply chain in Lifeline Skin Care as well as a shift in sales mix from lower to higher margin products in Lifeline Cell Technology.

As of September 30, 2013 and December 31, 2012, our cash and cash equivalents totaled $1.79 million and $0.65 million, respectively. At September 30, 2013, we had a working capital deficit of $2.38 million, compared to working capital of $0.40 million as of December 31, 2012. The working capital deficit is due to the fair value of warrant liability of $4.39 million recognized during the third quarter resulting from our financing transaction completed in July 2013.

Cash outflows from operations for the first nine months of 2013 were $4.23 million, down from $5.12 million in the corresponding period in 2012. Net cash provided by financing activities was $5.89 million for the nine months ended September 30, 2013, compared to $6.79 million in the corresponding period in 2012.

Conference Call and Webcast Details:

Date: Wednesday, November 13, 2013
Time: 11:00 a.m. Eastern Time
Conference Line (U.S.): 1-877-941-1428
International Dial-In: 1-480-629-9665
Conference ID: 4648561
Webcast: http://webcast.mzvaluemonitor.com/Cover.aspx?PlatformId=1293

Please dial in at least 10-minutes before the call to ensure timely participation.

A playback of the call will be available until 11:59 pm ET on November 27, 2013. To listen, call 1-877-870-5176 within the United States or 1-858-384-5517 when calling internationally. Please use the replay pin 4648561.

About International Stem Cell Corporation

International Stem Cell Corporation is focused on the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenetic, homozygous stem cell line that can be a source of therapeutic cells for hundreds of millions of individuals of differing genders, ages and racial background with minimal immune rejection after transplantation. hpSCs offer the potential to create the first true stem cell bank, UniStemCell™. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology (www.lifelinecelltech.com), and stem cell-based skin care products through its subsidiary Lifeline Skin Care (www.lifelineskincare.com). More information is available at www.internationalstemcell.com.

To subscribe to receive ongoing corporate communications, please click on the following link: http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0

To like our Facebook page or follow us on Twitter for company updates and industry related news, visit: www.facebook.com/InternationalStemCellCorporation and www.twitter.com/intlstemcell

Safe harbor statement

Statements pertaining to anticipated developments, expected changes in R&D expenses, progress of research and development, potential sales growth, new products and distribution channels and other opportunities for the company and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates,") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products and the management of collaborations, regulatory approvals, need and ability to obtain future capital, application of capital resources among competing uses, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the company's business, particularly those mentioned in the cautionary statements found in the company's Securities and Exchange Commission filings. The company disclaims any intent or obligation to update forward-looking statements.

                                                                            
                                                                            
            International Stem Cell Corporation and Subsidiaries            
                       (A Development Stage Company)                        
                   Condensed Consolidated Balance Sheets                    
                     (in thousands, except share data)                      
                                (Unaudited)                                 
                                                                            
                                               September 30,   December 31, 
                                                    2013           2012     
                                               -------------  ------------- 
Assets                                                                      
  Cash and cash equivalents                    $       1,792  $         654 
  Accounts receivable, net of allowance for                                 
   doubtful accounts of $19 and $4 at                                       
   September 30, 2013 and December 31, 2012,                                
   respectively                                          398            273 
  Inventory, net                                       1,360          1,199 
  Prepaid expenses and other current assets              407            456 
  Restricted cash                                         50             -- 
                                               -------------  ------------- 
                                                                            
    Total current assets                               4,007          2,582 
  Property and equipment, net                            851          1,134 
  Intangible assets, net                               2,036          1,634 
  Deposits and other assets                               33             20 
                                               -------------  ------------- 
                                                                            
    Total assets                               $       6,927  $       5,370 
                                               =============  ============= 
                                                                            
Liabilities, Redeemable Preferred Stock and                                 
 Stockholders' Equity (Deficit)                                             
  Accounts payable                             $         522  $         969 
  Accrued liabilities                                  1,056            730 
  Deferred revenue                                       156            233 
  Related party payable                                   16              5 
  Advances                                               250            250 
  Fair value of warrant liability                      4,389             -- 
                                               -------------  ------------- 
                                                                            
    Total current liabilities                          6,389          2,187 
                                               -------------  ------------- 
                                                                            
Convertible Redeemable Series G Preferred                                   
 stock, $0.001 par value, 5,000,000 shares                                  
 authorized, issued and outstanding at                                      
 September 30, 2013 and December 31, 2012,                                  
 liquidation preferences of $5,000 at                                       
 September 30, 2013 and December 31, 2012              4,941          4,941 
                                                                            
Commitments and contingencies                                               
                                                                            
Stockholders' Equity (Deficit)                                              
Series D Preferred stock, $0.001 par value, 50                              
 shares authorized, 43 issued and outstanding                               
 at September 30, 2013 and December 31, 2012,                               
 liquidation preferences of $4,320 at                                       
 September 30, 2013 and December 31, 2012                 --             -- 
Series B Preferred stock, $0.001 par value,                                 
 5,000,000 shares authorized, 300,000 issued                                
 and outstanding at September 30, 2013 and                                  
 December 31, 2012, liquidation preferences of                              
 $397 and $385 at September 30, 2013 and                                    
 December 31, 2012, respectively                          --             -- 
Series C Preferred stock, $0.001 par value, 0                               
 and 3,000,000 shares authorized, 0 and                                     
 2,000,000 issued and outstanding at September                              
 30, 2013 and December 31, 2012, respectively,                              
 liquidation preferences of $0 and $2,507 at                                
 September 30, 2013 and December 31, 2012,                                  
 respectively                                             --              2 
Common stock, $0.001 par value, 300,000,000                                 
 shares authorized, 134,169,565 and 87,388,815                              
 issued and outstanding at September 30, 2013                               
 and December 31, 2012, respectively                     134             87 
Additional paid-in capital                            74,967         69,945 
  Deficit accumulated during the development                                
   stage                                             (79,504)       (71,792)
                                               -------------  ------------- 
                                                                            
  Total stockholders' deficit                         (4,403)        (1,758)
                                               -------------  ------------- 
                                                                            
  Total liabilities, redeemable preferred                                   
   stock and stockholders' equity (deficit)    $       6,927  $       5,370 
                                               =============  ============= 
                                                                            
                                                                            
                                                                            
            International Stem Cell Corporation and Subsidiaries            
                       (A Development Stage Company)                        
              Condensed Consolidated Statements of Operations               
                   (in thousands, except per share data)                    
                                (Unaudited)                                 
                                                                            
                                                                  Inception 
                                                                   (August  
                                                                     17,    
                                                                    2001)   
                                                                   through  
                       Three Months Ended     Nine Months Ended   September 
                          September 30,         September 30,        30,    
                      --------------------  --------------------            
                         2013       2012       2013       2012       2013   
                      ---------  ---------  ---------  ---------  --------- 
Revenues                                                                    
  Product sales       $   1,670  $   1,187  $   4,412  $   3,320  $  16,610 
  Royalties and                                                             
   license                   --         --         --         --        135 
                      ---------  ---------  ---------  ---------  --------- 
                                                                            
    Total revenue         1,670      1,187      4,412      3,320     16,745 
                      ---------  ---------  ---------  ---------  --------- 
                                                                            
Development expenses                                                        
  Cost of sales             447        320      1,110        957      5,716 
  Research and                                                              
   development              932        900      2,627      2,702     24,520 
  Marketing                 632        477      1,823      1,521      7,762 
  General and                                                               
   administrative         1,362      1,570      4,461      5,364     43,589 
                      ---------  ---------  ---------  ---------  --------- 
                                                                            
    Total development                                                       
     expenses             3,373      3,267     10,021     10,544     81,587 
                      ---------  ---------  ---------  ---------  --------- 
                                                                            
Loss from development                                                       
 activities              (1,703)    (2,080)    (5,609)    (7,224)   (64,842)
                      ---------  ---------  ---------  ---------  --------- 
                                                                            
Other income (expense)                                                      
  Settlement with                                                           
   related company           --         --         --         --        (93)
  Miscellaneous                                                             
   expense                   --         (1)       (20)       (55)      (265)
  Dividend income            --         --         --         --         94 
  Interest expense           --         --         --         --     (2,225)
  Sublease income             5         --         18          7        334 
  Fair value of                                                             
   warrant liability                                                        
   in excess of                                                             
   proceeds              (1,390)        --     (1,390)        --     (1,390)
  Financing                                                                 
   transaction costs       (738)        --       (738)        --       (738)
  Change in fair value                                                      
   of warrant                                                               
   liability                 27         --         27         38     (1,330)
                      ---------  ---------  ---------  ---------  --------- 
                                                                            
    Total other                                                             
     expense, net        (2,096)        (1)    (2,103)       (10)    (5,613)
                      ---------  ---------  ---------  ---------  --------- 
                                                                            
Loss before income                                                          
 taxes                   (3,799)    (2,081)    (7,712)    (7,234)   (70,455)
Provision for income                                                        
 taxes                       --         --         --         --          7 
                      ---------  ---------  ---------  ---------  --------- 
                                                                            
      Net loss        $  (3,799) $  (2,081) $  (7,712) $  (7,234) $ (70,462)
                      =========  =========  =========  =========  ========= 
                                                                            
Deemed dividend on                                                          
 preferred stock             --         --         --     (1,375)    (1,375)
Dividends on preferred                                                      
 stock                       --         93         --       (129)    (8,097)
                      ---------  ---------  ---------  ---------  --------- 
                                                                            
Net loss attributable                                                       
 to common                                                                  
 stockholders         $  (3,799) $  (1,988) $  (7,712) $  (8,738) $ (79,934)
                      =========  =========  =========  =========  ========= 
                                                                            
Net loss per common                                                         
 share-basic and                                                            
 diluted              $   (0.03) $   (0.02) $   (0.07) $   (0.10)           
                      =========  =========  =========  =========            
                                                                            
Weighted average                                                            
 shares-basic and                                                           
 diluted                128,243     87,350    114,830     85,421            
                      =========  =========  =========  =========            
                                                                            

Contacts:
International Stem Cell Corporation
Dr. Simon Craw
Executive Vice President of Business Development
Phone: 760-940-6383
Email: ir@intlstemcell.com



Help employers find you! Check out all the jobs and post your resume.


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES